Progenics Pharmaceuticals (PGNX) 10-K2011 FY Annual report

Filed: 15 Mar 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abiraterone, absolute, accrual, acetate, Algeta, Alpharadin, ASA, Asia, auristatin, autoimmune, CEO, CFO, cGMP, consecutive, converged, CSO, Cubist, cytotoxic, decade, dedicated, deliverable, diagnostic, discharging, explored, founder, FTE, hurt, imposed, Medivation, MMAE, move, ordinary, owed, PDUFA, placebo, Pty, put, ratio, recall, reorientation, restructuring, serving, shift, South, sublicensee, suspension, thereunto, tumor, unpredictable, User, Warning, Zealand, Zytiga

Removed: Aaron, accommodation, accomplished, actively, ADARC, administer, aforementioned, albeit, amending, analyzed, assignment, assist, attributed, Biotech, block, budget, calculating, capable, Center, chemotherapy, cholesterol, consummation, contemplated, contingently, Conventional, create, Crompton, curative, debilitating, demonstrated, Determination, developmental, Diamond, dispose, effort, eleven, employing, entry, execution, extensively, Facet, fewer, forecast, forma, FUZEON, gene, granting, hereunto, humanized, impotence, incontinence, inhibitor, initiated, interferon, JCC, JDC, jointly, JSC, liver, localized, markdown, modified, multiple, murine, newest, offer, passage, pivotal, POI, prospectively, prostatectomy, ProVax, radical, recognizing, recombinant, register, relation, Replicon, repurchased, response, retail, retrospective, ribavirin, SELZENTRY, separated, shown, smaller, sourcing, standalone, Sublease, sublicensed, substantive, syndrome, thereunder, transferred, Treasurer, unamortized, unclear, unit, unmet, unreasonably, unrelated, Vector, viral, withheld

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PGNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

Progenics Pharmaceuticals, Inc.

Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends

(in thousands)


	Years Ended December 31,
	2011		2010			2009			2008			2007
Determination of earnings (loss):
Income (loss) from operations	$	10,381	$	(69,820	)	$	(30,612	)	$	(44,672	)	$	(43,688	)
Add:
Fixed charges	695		709			555			594			483

Earnings (loss), as adjusted	$	11,076	$	(69,111	)	$	(30,057	)	$	(44,078	)	$	(43,205	)

Fixed charges:

Estimate of interest within rental expense	695		709			555			594			483

Fixed charges	$	695	$	709		$	555		$	594		$	483

Preferred stock dividends	$	-	$	-		$	-		$	-		$	-


Ratio of earnings (loss) to fixed charges and preferred stock dividends	16		*			*			*			*
Coverage deficiency amount for total fixed charges and preferred stock dividends (1)		-	$	69,820		$	30,612		$	44,672		$	43,688

______________

(1) For the years ended 2007 through 2010, the Company’s coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.